Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure

Journal of the American College of Cardiology

Volumn 34, Issue 6, 1999, Pages 1794-1801

  Westheim, Arne S ^a   Bostrøm, Per ^b   Christensen, Carl C ^a   Parikka, Hanni ^c   Rykke, Einar O ^a   Toivonen, Lauri ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Helsinki University Hospital ^*  (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANDOXATRIL; FUROSEMIDE; PLACEBO; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; EXERCISE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN; MALE; MULTICENTER STUDY; NEUROENDOCRINOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033571768     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00435-0     Document Type: Article

References (15)

1. Conti CR. Heart failure: drug therapy in the nineties and beyond. Clin Cardiol 1993;16:459-60.
2. Van Zwieten PA. Pharmacotherapy of congestive heart failure. Currently used and experimental drugs. Pharm World Sci 1994;16:234-42.
3. Carson P. Pharmacologic treatment of congestive heart failure. Clin Cardiol 1996;19:271-7.
4. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
5. Richards AM, Ikram M, Yandle TG, Nicholls MA, Webster MWI, Espiner EA. Renal, haemodynamic and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1986;1:545-8.
6. Cody RJ, Atlas SA, Laragh JM, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74.
7. O'Connell JE, Jardine AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma arterial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992;10:271-7.
8. Kimmelstiel CD, Perrone R, Kilcoyne L, et al. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology 1996;87:46-53.
9. Elsner D, Muntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.
10. Northridge DB, Metcalfe MJ, Jackson NC, Dargie HJ. Neutral endopeptidase inhibition versus frusemide in mild heart failure: diuretic, hemodynamic and neuroendocrine effects (abstr). Eur Heart J 1991;12:374.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
12. Alderman MH, Madhavan S, Oot WL, Cohen H, Sealey JE, Laragh JH. Association of renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324: 1098-1104.
13. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Concensus Trial Study Group. Circulation 1990;82:1730-6.
14. Francis GS, Benedict C, Johnstone DE, et al., for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
15. Konstam MA, Rousseau MF, Kronenberg MW, et al., for the SOLVD Inverstigators. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.